Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Nov 15, 2022

TORRANCE, Calif., Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.